I've been a lurker here on this board for about a year now and have had some great success following the boards general picks (especially ENTA).
I've recently run into a company that's been completely ravaged over the past two weeks (no surprise). However, this one has fallen quite significantly over the past week, down ~40% over the last 5 days. The stock seems to be stabilizing here and is trading well below their IPO price back in February.
The company is uniQure (Nasdaq: QURE). The company's market cap is about $160 million, but if you take into account the cash on the balance sheet and cash from the February IPO, the company's enterprise value is closer to $60 million. Analysts are quite favorable on the stock, especially Piper Jaffray.
A few weeks ago, a competitor was bought out by Baxter. Research firm Piper Jaffray said the Baxter acquisition has a positive read-through for Uniqure. The deal validates other hemophilia gene therapy programs in development, most notably Uniqure's, according to the firm. Analyst Joshua Schimmer wrote that there are other gene therapy programs for hemophilia in development beside Uniqure's and Baxter's, but he believes Uniqure has an advantage since it will be important to be among the first to market. The analyst also said that the market is large enough to accommodate more than one gene therapy option. Piper reiterated its Overweight rating and $35 price target on Uniqure.
Given that QURE is trading at $9 currently, does anyone have any thoughts on the current value / potential of QURE?
Appreciate any thoughts.
Good luck to all...
AI
